Skip to main content

Table 2 Comorbidities, medications and ICU data of RIPC and control patients

From: Activities of cardiac tissue matrix metalloproteinases 2 and 9 are reduced by remote ischemic preconditioning in cardiosurgical patients with cardiopulmonary bypass

Variable Control (N = 17) RIPC (N = 18) P-value
Comorbidities    
Diabetes mellitus (N) 3 (17.6%) 4 (22.2%) 1.00
Hypercholesterolemia (N) 12 (70.6%) 9 (50.0%) 0.31
Stroke (N) 2 (11.8%) 1 (5.5%) 0.60
Arterial hypertension (N) 14 (82.3%) 15 (83.3) 1.00
Myocardial infarction (N) 3 (17.6%) 7 (38.8%) 0.26
Medications    
Beta-adrenergic-blockers (N) 10 (58.8%) 13 (72.2%) 0.49
ACE/AT-1-antagonists (N) 11 (64.7%) 8 (44.4%) 0.31
ASA/clopidogrel (N) 14 (82.3%) 13 (72.2%) 0.69
Calcium-channel blockers (N) 1 (5.9%) 3 (16.6%) 0.60
Cholesterol-lowering (N) 8 (47.1%) 9 (50.0%) 1.00
Insulin/metformin (N) 2 (11.8%) 3 (16.6%) 1.00
Diuretics (N) 5 (29.4%) 3 (16.6%) 0.44
ICU data    
ICU-stay (hours) 59 ± 57 28 ± 23 0.13
ICU-readmission (N) 0 (0%) 1 (5.5%) 1.00
Reoperation (N) 1 (5.9%) 0 (0%) 0.49
Arrythmia (N) 4 (23.5%) 7 (38.8%) 0.47
Ventilation time (hours) 26 ± 25 14 ± 5 0.15
Reintubation (N) 3 (17.6%) 1 (5.5%) 0.34